Back to search results

Tazemetostat with CAR T Cell Therapy for B-cell Lymphomas

This study is testing if giving a pill called tazemetostat before and after standard CAR T cell therapy is safe and effective for people with certain B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). Researchers believe this combination could help CAR T cells work better at finding and killing lymphoma cells without causing too many side effects. You would take tazemetostat pills for a period before and after your CAR T cell treatment, potentially for up to 12 months. The study aims to enroll 15 participants who have already received at least one prior treatment for their lymphoma and are eligible for CAR T cell therapy. The main goal is to see how many participants experience side effects.

Study design
This is a single-arm, open-label study, meaning all participants receive the same treatment and everyone knows what treatment is being given. It plans to enroll 15 participants.
What's involved
You would take tazemetostat pills twice a day before and after your CAR T cell therapy, for up to 12 months. You will be followed for up to 5 years after treatment.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 5 years after receiving CAR T cell therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05934838

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatment
Weill Medical College of Cornell University
~15 participants
Updated 2026-06-17 on ClinicalTrials.gov
What's tested:Tazemetostat Pill

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants who experience adverse events classified per CTCAEv5
Measured over From start of treatment until 30 days after the last dose of tazemetostat, for a maximum of approximately 13 months

Conditions

Follicular Lymphoma
B-Cell Lymphoma
Mantle Cell Lymphoma
Diffuse Large B Cell Lymphoma

Explore related trials

Diffuse Large B-Cell LymphomaFollicular LymphomaMantle Cell Lymphoma

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Caitlin K Gribbin, M.D. · PRINCIPAL_INVESTIGATOR · Weill Medical College of Cornell University

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Confirmed diagnosis of DLBCL, FL, or MCL
Eligible to receive standard of care CAR T cells
Have received at least 1 prior therapies

Exclusion

Active viral infection with HIV or hepatitis type B or C
Active, uncontrolled systemic fungal, bacterial or viral infection
Active treatment for another cancer
Pregnant or breastfeeding
Unable to take oral medication
Certain significant past medical history, such recent stroke, pulmonary embolism, myocardial infarction, congestive heart failure, uncontrolled hypertension, or certain arrhythmias

What this trial measures

  • Number of participants who experience adverse events classified per CTCAEv5From start of treatment until 30 days after the last dose of tazemetostat, for a maximum of approximately 13 months

    Adverse reactions will be graded as per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.